Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Large Increase in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 134,275 shares, an increase of 247.4% from the May 31st total of 38,648 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily trading volume, of 49,633 shares, the days-to-cover ratio is currently 2.7 days.

Hedge Funds Weigh In On Chemomab Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Private Wealth Services LLC purchased a new position in shares of Chemomab Therapeutics in the fourth quarter worth about $85,000. ADAR1 Capital Management LLC bought a new stake in shares of Chemomab Therapeutics in the fourth quarter valued at approximately $132,000. Finally, XTX Topco Ltd purchased a new stake in shares of Chemomab Therapeutics during the 4th quarter valued at approximately $31,000. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Price Performance

Shares of NASDAQ CMMB opened at $1.59 on Friday. Chemomab Therapeutics has a one year low of $1.35 and a one year high of $4.92. The business’s fifty day moving average price is $1.70 and its 200-day moving average price is $1.74. The stock has a market capitalization of $11.45 million, a PE ratio of -0.72 and a beta of 0.62.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.18). As a group, equities analysts expect that Chemomab Therapeutics will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $25.00.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.